ABSTRACT The high-affminty binding of benzomorphan drugs (ethylketocyclazocine and N-allylnorcyclazocine) and [DAIa2,DLeu ] enkephalin was examined in a mouse neuroblastoma-Chinese hamster brain clonal hybrid cell line 
The data presented suggest that benzomorphan drugs interact with three distinct highaffinity binding sites: (i) a site that binds enkephalin and morphine in addition to ethylketocyclazocine and N-allylnorcyclazocine; (ii) a site that binds both ethylketocyclazocine and N-allylnorcyclazocine but not enkephalin and morphine; and (iii) a site that binds N-allylnorcyclazocine but not enkephalin, morphine, or ethylketocyclazocine. The first of these sites was comparable to the 8 Physiological studies (1) (2) (3) have suggested that opiates and related narcotic drugs (benzomorphans) may have four distinct sites of action in the central nervous system-the so-called 8, l, K, and o opiate receptors. However, attempts to resolve this growing complexity biochemically by differential binding studies have been hindered by the heterogeneous nature of nerve tissue. Some success has been reported in differentiating separate classes ofopiate receptors on the basis ofeffects ofsodium, GTP, and divalent cations (4) (5) (6) (7) (8) but direct evidence of discrete receptor subpopulations has primarily come from studies in peripheral tissue preparations and clonal neurotumor cell lines (9, 10) enriched in a single high-affinity opiate binding site.
It is now generally accepted that opiate receptors (A subtype) that respond preferentially to morphine may be found in guinea pig ileum (1), whereas opiate receptors (8 subtype) that respond preferentially to enkephalin are in high concentration in the mouse vas deferens (1) and in mouse neuroblastoma N4TG1 and mouse neuroblastoma-rat glioma NG108-15 cells (4, 9, 10) . In addition, the coexistence of 8 and A receptors in rat brain homogenates has been recently demonstrated (11) by the use of phenoxybenzamine to inactivate unprotected binding sites for either enkephalin or morphine irreversibly. Thus, the existence ofphysically distinct enkephalin (8) and morphine (,u) receptors appears to be established.
In contrast, the concept of specific receptors that respond preferentially to benzomorphan drugs (K and or subtypes), as originally proposed by Martin and colleagues (2, 3) to explain the different physiological effects of ethylketocyclazocine, ketocyclazocine, and N-allynorcyclazocine, has not gained widespread acceptance. In fact, there has been little biochemical evidence to date in support of such a concept and it has been suggested that 8 and ,u opiate receptors may alone mediate the actions of benzomorphan drugs (6) (7) (8) 12) .
Such a two-site model (8 and ,u) does not adequately account for the diverse pharmacological properties of opiates and benzomorphans. In this paper we present biochemical evidence for the interaction ofbenzomorphan drugs with high-affinity binding sites that are distinct from receptors for enkephalin and morphine.
MATERIALS AND METHODS
[3H]Ethylketocyclazocine ( Binding assays were performed via a modification ofthe procedure described by Chang et al. (10) . Aliquots of crude membrane preparations [0.2 ml; 0.1-0.5 mg ofprotein as determined by the Lowry (14) procedure] in 50 mM Tris HCl (pH 7.4) were incubated for 45 min at 250C with various concentrations of radiolabeled ligand and unlabeled drug (final incubation volume 0.24 ml.) One milliliter ofice-cold 50 mM Tris HCl (pH 7.4) was added to each sample prior to filtration through Whatman GF/ B glass microfiber filters under vacuum, the filters were washed twice with 5.0 ml ofice-cold buffer, and the bound radioactivity was determined by liquid scintillation counting. Nonspecific binding was measured in the presence of a large excess AuM) of the respective unlabeled ligand. Data that one of the binding sites not shared by enkephalin, etorphine, or morphine also had little affinity for ethylketocyclazocine. The binding-ofibenzomorphan derivatives in NCB-20 cells was stereospecific (Fig. 4) in that a 1000-fold difference in potency was observed for the stereoisomers UM 1071-R (IC50 = 10 nM) and UM 1071-S (IC50 = 10,000 nM) in competition bind-*ing studies with 3 nM N-[3H]allylnorcyclazocine. This agrees with previous reports (16) .that only the R enantiomer is active in vivo.
DISCUSSION
Benzomorphans are an enigmatic group of opioid drugs which produce a morphine-like depression ofthe nociceptive response yet fail to suppress withdrawal symptoms in morphine-dependent animals (2, 3, (16) (17) (18) (19) . Detailed studies of the differential response to opiates and benzomorphans in dogs led Martin and coworkers (2, 3) to propose the existence of three discrete subpopulations of opiate receptors-p, K, and o. The prototypical A agonist morphine both suppressed abstinence and produced analgesia in morphine-dependent dogs, whereas ethylketocyclazocine and ketocyclazocine neither suppressed. nor precipitated abstinence in morphine-dependent animals but did produce naloxone-reversible analgesia (2, 3) . It was therefore concluded that ethylketocyclazocine has a site of action, designated as the K receptor, distinct from morphine (Au) receptors.
Another type of naloxone-reversible effect-behavioral excitation without inducing analgesia or depressing abstinence in morphine-and ketocyclazocine-dependent dogs-was observed (2) with. the benzomorphan derivative N-allylnorcyclazocine (SKF 10,047). To explain. this, the site mediating this response was designated thear receptor. Behavioral studies in monkeys, rats, and mice (16) (17) (18) (19) and electrophysiological stud- ies in guinea pig ileum preparations (1, 19) have provided support for the concept that benzomorphans, such as ethylketocyclazocine and bremazocine, may exert their pharmacological actions at sites other than those previously characterized as morphine (,u) and enkephalin (8) receptors.
In this investigation we have demonstrated that benzomorphan drugs interact stereospecifically with multiple binding sites in a somatic cell hybrid NCB-20. One of the high-affinity binding sites appears to be identical to the enkephalin (8) receptor found in neurotumor cell.lines NG108-15 and N4TG1 (4, 9, 10) , rat brain homogenates (1, 4, 11) , and mouse vas deferens (1). The other high-affinity sites expressed in NCB-20 cells, which bind benzomorphan drugs preferentially, have not been previously described. Both ethylketocyclazocine (a putative K agonist) and N-allylnorcyclazocine (a putative oagonist) bind to a site which is not occupied by enkephalin or the classical opiate agonists morphine and etorphine. Furthermore, N-allylnorcyclazocine binds to a separate site having little affinity for enkephalin, morphine,.etorphine, or ethylketocyclazocine. Based on differences in the selectivity of the two specific benzomorphan binding sites for ethylketocyclazocine, it may not be unreasonable to suggest that these sites are equivalent to the K and o opiate receptor subtypes defined by Martin et al. (2) .
Additional support for~the contention that specific receptors for benzomorphan drugs do exist comes from the observation that [3H]ethylketocyclazocine binds to what has been tentatively called a K site in guinea pig brain homogenates (20 Therefore, they suggested that the analgesic effects of putative K agonists (e.g., ethylketocyclazocine) may be mediated through ,u receptors and that the behavioral effects ofputative a agonists (e.g., N-allylnorcyclazocine) may be mediated through 8 receptors. In independent studies, Pasternak (7) We would agree that benzomorphan drugs may exert some of their effects through enkephalin (8) and morphine (,u) receptors, but a two-site model (8 and ,) cannot explain all of the pharmacological properties associated with this unique group of narcotics. Specifically, a two-site model cannot explain why benzomorphans fail to suppress or precipitate abstinence in morphine-dependent animals (2, 3, (16) (17) (18) (19) . Benzomorphan drugs must have sites of action that are distinct from those of enkephalin and morphine. We have presented evidence for their existence in a neurotumor hybrid cell line.
